Treatment of atypical femoral fracture with teriparatide: case report
Authors:
Rosa Jan 1; Bouda Václav 2; Kasalický Petr 1
Authors‘ workplace:
Osteocentrum, Affidea Praha s. r. o.
1; Oddělení zobrazovacích metod, Affidea Praha s. r. o.
2
Published in:
Clinical Osteology 2020; 25(2): 93-98
Category:
Overview
Atypická fraktura femoru (AFF) je vzácným nežádoucím účinkem dlouhodobé aplikace bisfosfonátů nebo denosumabu. Předkládáme popis případu pacientky léčené pro osteoporózu bisfosfonáty (celkem 104 měsíců). Na základě prodromálních příznaků byla zobrazovacími metodami (RTG, MRI, kostní scintigrafie) diagnostikována inkompletní atypická fraktura levé kosti stehenní. Přerušení podávání bisfosfonátu, odlehčení končetiny a šestiměsíční aplikace teriparatidu vedly ke zhojení zlomeniny. U pacientů užívajících antiresorpční léčbu osteoporózy po dobu delší než 4 roky je nezbytné pravidelné dotazování na prodromální příznaky AFF.
Keywords:
teriparatide – bisphosphonates – atypical femoral fracture
Sources
Armamento-Villareal R, Napoli N. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. NEJM 2006; 355(9): 2048. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMc062268>.
Black DM, Abrahamsen Bo, Bouxsein ML et al. Atypical Femur Fractures – Review of epidemiology, relationship to bisphosphonates, prevention and clinical management. Endocrine Rev 2019; 40(2): 333–368. Dostupné z DOI: <http://dx.doi.org/10.1210/er.2018–00001>.
Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2014; 29(1): 1–23. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1998>.
Bala A, Gaillard F. Insufficiency fracture. Dostupné z WWW: <https://radiopaedia.org/articles/insufficiency-fracture>.
Shane E, Burr D, Ebeling PR et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American society for bone and mineral research. J Bone Miner Res 2010; 25(11): 2267–2294. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.253>.
Rizzoli R, Akesson K, Bouxsein M et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European society on clinical and economic aspects of osteoporosis and osteoarthritis and International osteoporosis foundation working group report. Osteoporos Int 2011; 22(2): 373–390. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–010–1453–5>.
Schilcher J, Koeppen V, Aspenberg P et al. Risk of atypical femoral fracture during and after bisphosphonate use Full report of a nationwide study. Acta Orthop 2015; 86(1): 100–107. Dostupné z DOI: <http://dx.doi.org/10.3109/17453674.2015.1004149>.
van de Laarschot DM, Smits AAA, Buitendijk SKC et al. Scrrening for atypical femur fractures using extended femur scans by DXA. J Bone Mineral Res 2017;32(8): 1632–1639. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.3164>.
Chang-Wug O, Jong-Keon O, Ki-Chul P et al. Prophylactic Nailing of Incomplete Atypical Femoral Fractures. Sci World J 2013; 450148. Dostupné z DOI: <http://dx.doi.org/10.1155/2013/450148>.
Schemitsch C, Kuzky P, McKee M. Atypical femoral fracture despite prophylactic intramedullary nailing: A case report. JBJS Case Connect 2015; 5(3): e57. Dostupné z DOI: <http://dx.doi.org/10.2106/JBJS.CC.N.00066>.
van de Laarschot DM, McKenna M, Zillikens MC. Medical management of atypical femur fractures: a systematic review. J Clin Endocrinol Metab 2020; 105(5): 1682–1699. Dostupné z DOI: <http://doi: 10.1210/clinem/dgz295>.
Obermayer-Pietsch B, Marin F, McCloskey EV et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008; 23(10): 1591–1600. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.080506>.
Krege JH, Lane, NE, Harris JM et al. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int 2014; 25(9): 2159–2171. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–014–2646–0>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology OsteologyArticle was published in
Clinical Osteology
2020 Issue 2
Most read in this issue
- Bone turnover markers in osteoporosis: a common statement on their use of the Society for Metabolic Bone Diseases within the Czech Medical Association of J.E. Purkyne (SMBD CzMA JEP) and the Czech Society of Clinical Biochemistry within the Czech Medical Association of J.E. Purkyne (CSCB CzMA JEP)
- Osteolytic deposits of the pelvis leading to the diagnosis of primary hyperparathyreosis: case report
- Osteoporosis on systemic mastocytosis: case report
- Definition of osteoporotic (fragility) fracture: a statement of the Society for Metabolic Bone Diseases within the Czech Medical Association of J.E. Purkyne (SMOS CzMa of JEP)